Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19

被引:18
作者
Kutsuna, Satoshi [1 ]
Asai, Yusuke [2 ]
Matsunaga, Akihiro [3 ]
Kinoshita, Noriko [1 ]
Terada, Mari [1 ]
Miyazato, Yusuke [1 ]
Nakamoto, Takato [1 ]
Suzuki, Tetsuya [1 ]
Saito, Sho [1 ]
Endo, Mio [2 ]
Kanda, Kohei [1 ]
Kenji, Maeda [4 ]
Takasaki, Jin [5 ]
Hojo, Masayuki [5 ]
Ishizaka, Yukihito [3 ,6 ]
Ohmagari, Norio [1 ]
机构
[1] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo, Japan
[2] Natl Ctr Global Hlth & Med, AMR Clin Reference Ctr, Tokyo, Japan
[3] Natl Ctr Global Hlth & Med, Dept Intractable Dis, Tokyo, Japan
[4] Natl Ctr Global Hlth & Med Res Inst, Dept Refractory Viral Infect, Tokyo, Japan
[5] Natl Ctr Global Hlth & Med, Dept Resp Dis, Tokyo, Japan
[6] Natl Ctr Global Hlth & Med Res Inst, Gen, Tokyo, Japan
关键词
COVID-19; SARS-CoV-2; Convalescent; Anti-SARS-CoV-2 spike protein antibody;
D O I
10.1016/j.jiac.2021.01.006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Among patients with coronavirus disease 2019 (COVID-19), the factors that affect anti severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody production remain unclear. This study aimed to identify such factors among patients convalescing from COVID-19. Methods: This study comprised patients who had been diagnosed with COVID-19 between January 1 and June 30, 2020 and gave consent for anti-SARS-CoV-2 spike protein antibody measurement using enzyme linked immunosorbent assay during their acute and/or convalescent phases. Factors related to elevated antibody titers and the relationship between the days from disease onset and the development of antibody titers were assessed. Results: A total of 84 participants enrolled in the study. Nineteen participants had antibody titers measured during the convalescent phase only, and 65 participants had antibody titers measured during the acute and convalescent phases. The antibody titers peaked in weeks 5 and 6. The stepwise multivariate log-normal analysis revealed that male sex (P = 0.04), diabetes mellitus (P = 0.03), and high C reactive protein levels during the disease course (P < 0.001) were associated with elevated IgG antibodies. Glucocorticoid use was not associated with antibody titers. Conclusion: The study found that high values of maximum CRP levels during the acute phase, male sex, and diabetes mellitus were associated with elevated antibody titers. Antibody titers tended to be highest in the first 5 or 6 weeks after the onset of symptoms. (c) 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:808 / 813
页数:6
相关论文
共 34 条
[1]   Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design [J].
Barone, Paul ;
DeSimone, Robert A. .
TRANSFUSION, 2020, 60 (06) :1123-1127
[2]  
Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI [10.1056/NEJMoa2007764, 10.1056/NEJMc2022236]
[3]   Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J].
Chen, Nanshan ;
Zhou, Min ;
Dong, Xuan ;
Qu, Jieming ;
Gong, Fengyun ;
Han, Yang ;
Qiu, Yang ;
Wang, Jingli ;
Liu, Ying ;
Wei, Yuan ;
Xia, Jia'an ;
Yu, Ting ;
Zhang, Xinxin ;
Zhang, Li .
LANCET, 2020, 395 (10223) :507-513
[4]  
Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
[5]   Effectiveness of convalescent plasma therapy in severe COVID-19 patients [J].
Duan, Kai ;
Liu, Bende ;
Li, Cesheng ;
Zhang, Huajun ;
Yu, Ting ;
Qu, Jieming ;
Zhou, Min ;
Chen, Li ;
Meng, Shengli ;
Hu, Yong ;
Peng, Cheng ;
Yuan, Mingchao ;
Huang, Jinyan ;
Wang, Zejun ;
Yu, Jianhong ;
Gao, Xiaoxiao ;
Wang, Dan ;
Yu, Xiaoqi ;
Li, Li ;
Zhang, Jiayou ;
Wu, Xiao ;
Li, Bei ;
Xu, Yanping ;
Chen, Wei ;
Peng, Yan ;
Hu, Yeqin ;
Lin, Lianzhen ;
Liu, Xuefei ;
Huang, Shihe ;
Zhou, Zhijun ;
Zhang, Lianghao ;
Wang, Yue ;
Zhang, Zhi ;
Deng, Kun ;
Xia, Zhiwu ;
Gong, Qin ;
Zhang, Wei ;
Zheng, Xiaobei ;
Liu, Ying ;
Yang, Huichuan ;
Zhou, Dongbo ;
Yu, Ding ;
Hou, Jifeng ;
Shi, Zhengli ;
Chen, Saijuan ;
Chen, Zhu ;
Zhang, Xinxin ;
Yang, Xiaoming .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (17) :9490-9496
[6]   A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity [J].
Goren, Andy ;
Vano-Galvan, Sergio ;
Wambier, Carlos Gustavo ;
McCoy, John ;
Gomez-Zubiaur, Alba ;
Moreno-Arrones, Oscar M. ;
Shapiro, Jerry ;
Sinclair, Rodney D. ;
Gold, Michael H. ;
Kovacevic, Maja ;
Mesinkovska, Natasha Atanaskova ;
Goldust, Mohamad ;
Washenik, Ken .
JOURNAL OF COSMETIC DERMATOLOGY, 2020, 19 (07) :1545-1547
[7]   Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan [J].
Ito, Kyoji ;
Ohmagari, Norio ;
Mikami, Ayako ;
Sugiura, Wataru .
GLOBAL HEALTH & MEDICINE, 2020, 2 (02) :96-101
[8]   Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses [J].
Jiang, Shibo ;
Hillyer, Christopher ;
Du, Lanying .
TRENDS IN IMMUNOLOGY, 2020, 41 (05) :355-359
[9]   Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19 [J].
Boelke, Edwin ;
Matuschek, Christiane ;
Fischer, Johannes C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (17) :1694-1695
[10]   Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial [J].
Li, Ling ;
Zhang, Wei ;
Hu, Yu ;
Tong, Xunliang ;
Zheng, Shangen ;
Yang, Juntao ;
Kong, Yujie ;
Ren, Lili ;
Wei, Qing ;
Mei, Heng ;
Hu, Caiying ;
Tao, Cuihua ;
Yang, Ru ;
Wang, Jue ;
Yu, Yongpei ;
Guo, Yong ;
Wu, Xiaoxiong ;
Xu, Zhihua ;
Zeng, Li ;
Xiong, Nian ;
Chen, Lifeng ;
Wang, Juan ;
Man, Ning ;
Liu, Yu ;
Xu, Haixia ;
Deng, E. ;
Zhang, Xuejun ;
Li, Chenyue ;
Wang, Conghui ;
Su, Shisheng ;
Zhang, Linqi ;
Wang, Jianwei ;
Wu, Yanyun ;
Liu, Zhong .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05) :460-470